The $400,000 2026 Merkin Prize, administered by the Broad Institute, recognizes the researchers whose complementary work turned the cochlear implant into a viable clinical option now used by more than one million people worldwide.
Five scientists and engineers — Graeme Clark, Erwin Hochmair, Ingeborg Hochmair, Michael Merzenich, and Blake Wilson — have been jointly awarded the 2026 Richard N Merkin Prize in Biomedical Technology for their roles in developing the modern cochlear implant, the medical device that interfaces with the nervous system to provide a sense of hearing. The prize, worth $400,000 and shared among the five recipients, is administered by the Broad Institute of MIT and Harvard.
The Merkin Prize recognizes novel technologies with demonstrable real-world impact on human health. A selection committee of nine scientific leaders from the US and Europe evaluated nominations before choosing the cochlear implant team for this year’s honors. The winners will be recognized at a prize ceremony in September.
“What makes this work especially remarkable is that it required not one breakthrough but several, achieved by different people working across different disciplines and different countries over many decades,” says Harold Varmus, Nobel laureate and chair of the Merkin Prize selection committee, in a release. “The Merkin Prize gives us an opportunity to recognize several of the individuals whose contributions were essential to that success.”
The Science Behind the Device
The cochlear implant works by bypassing damaged or absent hair cells in the cochlea — the most common cause of severe or complete hearing loss — and delivering electrical stimulation directly to the auditory nerve. Unlike traditional hearing aids, which amplify sound, cochlear implants convert sounds into electrical signals that the auditory nerve carries to the brain. Because hair cells do not regenerate once lost, amplification alone cannot restore meaningful hearing for individuals with severe loss.
The five laureates, working independently across different countries and decades, each contributed critical elements to make that concept clinically practical.
The Laureates and Their Contributions
Ingeborg Hochmair and Erwin Hochmair — then at Vienna Technical University — collaborated beginning in 1975 to develop a microelectronics multi-channel cochlear implant featuring a subcutaneous receiver and a flexible electrode array threaded into the cochlea. On Dec 16, 1977, the device was implanted in a deaf patient in Vienna — among the earliest multi-channel implant procedures on record. The Hochmairs later founded Med-El, now one of the world’s largest manufacturers of hearing implants.
Graeme Clark, an ear, nose, and throat surgeon at the University of Melbourne whose father was deaf, completed his PhD work in 1969 having concluded that multi-channel electrical stimulation was necessary for speech understanding. He led animal behavior, biological safety, and engineering studies before performing his first implant procedure on Aug 1, 1978. His team’s work identified a speech code that enabled a patient to understand aspects of spoken communication without lipreading. That research contributed to the FDA approval of the multi-channel implant in 1985 and the founding of Cochlear, where Clark continued his work on cochlear implants and speech processing systems with support from the US National Institutes of Health.
Michael Merzenich led an interdisciplinary team at the University of California, San Francisco, beginning in the early 1970s to establish the neurophysiological basis for cochlear implants and determine how best to connect implants to the brain. In 1974, he convened a public meeting with more than 50 speech and hearing experts and key government officials to build a coordinated plan for advancing multi-channel implant development. His team’s fundamental research on electrode array design and implant safety later led to the commercialization of implants in the late 1980s through Advanced Bionics, which continues to produce the devices today.
Blake Wilson addressed a persistent performance gap that emerged once multielectrode implants entered clinical use in the mid-1980s: results were uneven, with many users unable to understand speech reliably. In 1989, working at Duke University Medical Center and what is now RTI International in Research Triangle Park, NC, Wilson and his team developed continuous interleaved sampling (CIS), a signal processing strategy that enabled higher levels of speech understanding for more than 80% of cochlear implant users. That advance helped shift the cochlear implant from an experimental treatment into mainstream clinical practice.
Clinical and Scientific Impact
More than one million people have now received cochlear implants. For a detailed overview of current systems from MED-EL, Cochlear, Advanced Bionics, and others, see The Hearing Review‘s cochlear implant systems comparison.
Beyond audiology, research into cochlear implants has expanded scientific understanding of how the brain adapts to sound and language input. The technology has also influenced the development of emerging neural prostheses for vision and motor function by demonstrating that stimulating a few dozen electrode sites can reliably generate a sensory experience.
“This whole story is a beautiful convergence of fields,” says Emery Brown, the Edward Hood Taplin professor of medical engineering and professor of computational neuroscience at MIT and a member of the Merkin Prize selection committee, in a release. “You had neurophysiology and basic neuroscience to figure out how this organ works, a layer of engineering and technology development to stimulate it, and then behavioral science to confirm that patients were actually perceiving what was being delivered. It’s a true example of how basic, fundamental science can act as the backbone on which to create life-changing technologies.”
Richard Merkin, MD, founder and CEO of Heritage Provider Network and the prize’s namesake, echoed that sentiment. “Their achievement is stunning and represents the best of my intentions for the Merkin Prize in Biomedical Technology at the Broad Institute,” he says, in a release.
